Compare · ALIM vs PFE
ALIM vs PFE
Side-by-side comparison of Alimera Sciences Inc. (ALIM) and Pfizer Inc. (PFE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALIM and PFE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PFE is the larger of the two at $304.95B, about 9767.2x ALIM ($31.2M).
- PFE has hit the wire 10 times in the past 4 weeks while ALIM has been quiet.
- PFE has more recent analyst coverage (25 ratings vs 5 for ALIM).
- Company
- Alimera Sciences Inc.
- Pfizer Inc.
- Price
- $5.54+0.00%
- $26.98+1.20%
- Market cap
- $31.2M
- $304.95B
- 1M return
- -
- -1.21%
- 1Y return
- -
- +17.13%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2010
- News (4w)
- 0
- 10
- Recent ratings
- 5
- 25
Alimera Sciences Inc.
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest ALIM
- SEC Form 15-12G filed by Alimera Sciences Inc.
- SEC Form EFFECT filed by Alimera Sciences Inc.
- SEC Form EFFECT filed by Alimera Sciences Inc.
- SEC Form 4 filed by Chief Financial Officer Maltz Elliot
- SEC Form 4 filed by Director Kaseta Michael
- Chief Marketing Officer & SVP Holland David returned 187,756 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Snisarenko John returned 10,000 shares to the company, closing all direct ownership in the company (SEC Form 4)
- President and CEO Eiswirth Richard S Jr returned 324,018 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Pax Margaret
- Director Pizzo Peter J. Iii returned 500 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest PFE
- Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company
- Pfizer Declares Second-Quarter 2026 Dividend
- Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
- U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- SEC Form 4 filed by Bourla Albert
- SEC Form 4 filed by Bourla Albert
- SEC Form 3 filed by new insider Hancock Dennis P
- Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
- Telix Strengthens Board with Additional Director Appointments
- AI-Enhanced Robotics in Pharma Manufacturing Signals Major Efficiency, Margin Expansion Opportunities